Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
Blanca Bolea-Alamañac(University of Bristol), David Nutt(Imperial College London), Philip Asherson(King's College - North Carolina), John K. Nash(North Wales Hospital), David J. Heal(Nexor (United Kingdom)), Paramala Santosh(King's College London), David Coghill(The University of Melbourne), Susan Young(Brunel University of London), Kapil Sayal(University of Nottingham), Edmund Sonuga‐Barke(King's College London), Marios Adamou(South West Yorkshire Partnership NHS Foundation Trust), Stephen Bazire(Norfolk and Suffolk NHS Foundation Trust), Ulrich Müller(American Academy of Allergy, Asthma and Immunology)
Cited by 284
Related Papers
Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder
|Nature Genetics|2018|2.3k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k
Characterizing cognition in ADHD: beyond executive dysfunction
|Trends in Cognitive Sciences|2006|1.2k
Spontaneous attentional fluctuations in impaired states and pathological conditions: A neurobiological hypothesis
|Neuroscience & Biobehavioral Reviews|2007|889